JAGUAR HEALTH INC (JAGX) Fundamental Analysis & Valuation

NASDAQ:JAGX • US47010C8881

Current stock price

0.3619 USD
-0.03 (-6.68%)
Last:

This JAGX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. JAGX Profitability Analysis

1.1 Basic Checks

  • JAGX had negative earnings in the past year.
  • In the past year JAGX has reported a negative cash flow from operations.
  • JAGX had negative earnings in each of the past 5 years.
  • JAGX had a negative operating cash flow in each of the past 5 years.
JAGX Yearly Net Income VS EBIT VS OCF VS FCFJAGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -139.80%, JAGX is doing worse than 83.77% of the companies in the same industry.
Industry RankSector Rank
ROA -139.8%
ROE N/A
ROIC N/A
ROA(3y)-97.74%
ROA(5y)-98.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JAGX Yearly ROA, ROE, ROICJAGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K 4K 6K

1.3 Margins

  • JAGX has a Gross Margin of 67.21%. This is in the better half of the industry: JAGX outperforms 74.87% of its industry peers.
  • In the last couple of years the Gross Margin of JAGX has remained more or less at the same level.
  • JAGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.83%
GM growth 5Y0.66%
JAGX Yearly Profit, Operating, Gross MarginsJAGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. JAGX Health Analysis

2.1 Basic Checks

  • JAGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • JAGX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for JAGX has been increased compared to 5 years ago.
  • The debt/assets ratio for JAGX is higher compared to a year ago.
JAGX Yearly Shares OutstandingJAGX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
JAGX Yearly Total Debt VS Total AssetsJAGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • JAGX has an Altman-Z score of -18.77. This is a bad value and indicates that JAGX is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of JAGX (-18.77) is worse than 84.29% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.77
ROIC/WACCN/A
WACC1.86%
JAGX Yearly LT Debt VS Equity VS FCFJAGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • JAGX has a Current Ratio of 0.50. This is a bad value and indicates that JAGX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • JAGX has a worse Current ratio (0.50) than 93.72% of its industry peers.
  • A Quick Ratio of 0.29 indicates that JAGX may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.29, JAGX is not doing good in the industry: 94.76% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.5
Quick Ratio 0.29
JAGX Yearly Current Assets VS Current LiabilitesJAGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. JAGX Growth Analysis

3.1 Past

  • JAGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.16%, which is quite impressive.
  • The Revenue has decreased by -1.52% in the past year.
  • Measured over the past years, JAGX shows a small growth in Revenue. The Revenue has been growing by 4.17% on average per year.
EPS 1Y (TTM)31.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.98%
Revenue 1Y (TTM)-1.52%
Revenue growth 3Y-1.26%
Revenue growth 5Y4.17%
Sales Q2Q%-6.64%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • JAGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 116.65% yearly.
EPS Next Y76.14%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year30%
Revenue Next 2Y277.59%
Revenue Next 3Y200.81%
Revenue Next 5Y116.65%

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
JAGX Yearly Revenue VS EstimatesJAGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
JAGX Yearly EPS VS EstimatesJAGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2019 2020 2021 2022 2023 2024 2025 2026 -200M -400M -600M -800M -1B

More info and screens

Find the best growth stocksShow best growing peers

0

4. JAGX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for JAGX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JAGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JAGX Price Earnings VS Forward Price EarningsJAGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JAGX Per share dataJAGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JAGX Dividend Analysis

5.1 Amount

  • No dividends for JAGX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JAGX Fundamentals: All Metrics, Ratios and Statistics

JAGUAR HEALTH INC

NASDAQ:JAGX (4/27/2026, 9:48:04 AM)

0.3619

-0.03 (-6.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-07
Earnings (Next)05-13
Inst Owners1%
Inst Owner Change0%
Ins Owners6.49%
Ins Owner Change1.27%
Market Cap4.71M
Revenue(TTM)11.51M
Net Income(TTM)-53.58M
Analysts85.71
Price Target16.32 (4409.53%)
Short Float %4.39%
Short Ratio0.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-21.83%
Min Revenue beat(2)-24.68%
Max Revenue beat(2)-18.98%
Revenue beat(4)0
Avg Revenue beat(4)-19.63%
Min Revenue beat(4)-24.68%
Max Revenue beat(4)-11.83%
Revenue beat(8)1
Avg Revenue beat(8)-17.1%
Revenue beat(12)3
Avg Revenue beat(12)-14.48%
Revenue beat(16)5
Avg Revenue beat(16)-4.73%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-37.61
EYN/A
EPS(NY)-5.79
Fwd EYN/A
FCF(TTM)-1.82
FCFYN/A
OCF(TTM)-1.82
OCFYN/A
SpS0.88
BVpS-1.33
TBVpS-2.56
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -139.8%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.21%
FCFM N/A
ROA(3y)-97.74%
ROA(5y)-98.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.83%
GM growth 5Y0.66%
F-Score3
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.14%
Cap/Sales 0.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.5
Quick Ratio 0.29
Altman-Z -18.77
F-Score3
WACC1.86%
ROIC/WACCN/A
Cap/Depr(3y)4.77%
Cap/Depr(5y)19.84%
Cap/Sales(3y)0.78%
Cap/Sales(5y)3.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.98%
EPS Next Y76.14%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.52%
Revenue growth 3Y-1.26%
Revenue growth 5Y4.17%
Sales Q2Q%-6.64%
Revenue Next Year30%
Revenue Next 2Y277.59%
Revenue Next 3Y200.81%
Revenue Next 5Y116.65%
EBIT growth 1Y-46.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.39%
OCF growth 3YN/A
OCF growth 5YN/A

JAGUAR HEALTH INC / JAGX Fundamental Analysis FAQ

What is the fundamental rating for JAGX stock?

ChartMill assigns a fundamental rating of 1 / 10 to JAGX.


What is the valuation status of JAGUAR HEALTH INC (JAGX) stock?

ChartMill assigns a valuation rating of 0 / 10 to JAGUAR HEALTH INC (JAGX). This can be considered as Overvalued.


How profitable is JAGUAR HEALTH INC (JAGX) stock?

JAGUAR HEALTH INC (JAGX) has a profitability rating of 1 / 10.


What is the expected EPS growth for JAGUAR HEALTH INC (JAGX) stock?

The Earnings per Share (EPS) of JAGUAR HEALTH INC (JAGX) is expected to grow by 76.14% in the next year.